|
|
|
|
|
|
Sponsors and Collaborators: |
Northwestern Ophthalmic Institute S.C. Research to Prevent Blindness |
Information provided by: | Northwestern Ophthalmic Institute S.C. |
ClinicalTrials.gov Identifier: | NCT00675207 |
The purpose of this study is to compare the efficacy of brimonidine Purite, dorzolamide, and brinzolamide in reducing intraocular pressure when added to prostaglandin analog therapy (bimatoprost, latanoprost, or travoprost) in patients with glaucoma or ocular hypertension.
Condition | Intervention | Phase |
Primary Open Angle Glaucoma Ocular Hypertension |
Drug: Brimonidine purite 0.15% Drug: Dorzolamide 2% Drug: Brinzolamide 1% |
Phase IV |
Genetics Home Reference related topics: | early-onset glaucoma |
MedlinePlus related topics: | Glaucoma High Blood Pressure |
Drug Information available for: | Brimonidine Brimonidine Tartrate Dorzolamide Dorzolamide hydrochloride Azopt |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Single Blind (Investigator), Active Control, Parallel Assignment, Efficacy Study |
Official Title: | Comparison of Brimonidine 0.15% Purite, Dorzolamide 2%, and Brinzolamide 1% as Adjunctive Therapy to Prostaglandin Analogs |
Enrollment: | 120 |
Study Start Date: | January 2006 |
Study Completion Date: | July 2007 |
Primary Completion Date: | July 2007 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
1: Active Comparator
Brimonidine purite 0.15%
|
Drug: Brimonidine purite 0.15%
A single drop of brimonidine purite 0.15% ophthalmic solution administered topically in the eye 3 times daily.
|
2: Active Comparator
Dorzolamide 2%
|
Drug: Dorzolamide 2%
A single drop of dorzolamide 2% ophthalmic solution administered topically in the eye 3 times daily.
|
3: Active Comparator
Brinzolamide 1%
|
Drug: Brinzolamide 1%
A single drop of brinzolamide 1% ophthalmic solution administered topically in the eye 3 times daily.
|
Ages Eligible for Study: | 41 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Illinois | |||||
Northwestern Ophthalmic Institute S.C. | |||||
Glenview, Illinois, United States, 60026 |
Northwestern Ophthalmic Institute S.C. |
Research to Prevent Blindness |
Principal Investigator: | Thomas E. Bournias, MD | Northwestern Ophthalmic Institute S.C. |
Responsible Party: | Northwestern Ophthalmic Institute S.C. ( Thomas E. Bournias ) |
Study ID Numbers: | NWOIADJ 2006 |
First Received: | May 6, 2008 |
Last Updated: | May 6, 2008 |
ClinicalTrials.gov Identifier: | NCT00675207 |
Health Authority: | United States: Institutional Review Board |
|
|
|
|
|
|